WarenkorbDrucken
Falk Foundation | Dr. Falk
You are here:  PatientsDiseases and TreatmentLiver DiseasesDegeneration of the Liver (Hepatic Steatosis)
Further Information

Primary Biliary Cirrhosis

Primary Sclerosing Cholangitis

Fatty Liver Disease

Hepatitis

Autoimmune Hepatitis

Liver Cirrhosis

Hepatic Encephalopathy

Hepatocellular Carcinoma


Fatty Liver Disease

One of the most common changes to the liver is fatty liver disease. This term describes hepatocellular steatosis, multiple deposits of fats (triglycerides) in the liver cells. It is caused by chronic damage to the liver which in the majority of cases is caused by excessive alcohol consumption. Damage to the liver can be measured by the increase in liver function tests.
Fatty liver disease is a disease which can be reversed, unlike, for example, cirrhosis of the liver. If alcohol consumption is stopped, the situation in the liver can often return to normal due to the high regenerative capacity of this organ.
Alcohol is not the only cause of fatty liver disease. Scientists are currently increasingly discussing another form known as non-alcoholic steatohepatitis (NASH), a type of fatty liver disease associated with inflammatory changes that are not caused by high alcohol consumption levels. The specific causes of NASH are not known but the disease occurs more frequently in overweight or diabetic patients. One of the most important therapeutic measures is therefore moderate weight reduction, physical activity and the optimal treatment of concomitant diseases.


Patienten für laufende Studie zu MORBUS CROHN gesucht!

Klinische Studie zur Beurteilung eines neuen, sich in der Erprobung befindlichen biologischen Medikaments. Der Name der Studie ist TRUST-2, was für „TRichUris Suis ova Trial“ steht.

Mehr als 200 Patienten mit MORBUS CROHN haben das sich in der Erprobung befindende Studienmedikament bisher in klinischen Studien eingenommen.

Die Studien zeigen eine Abnahme der Krankheitsaktivität und in der Mehrzahl der Fälle wurde Remission (beschwerdefreie Phase) erzielt. Die bisher beobachteten Nebenwirkungen betrafen zumeist den Verdauungstrakt.